At a glance
ClinicalIndex Comparison RecordN/ACompleted· 449 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA.
In Brief
An observational study for Non-small Cell Lung Cancer. Completed, enrolled 449 participants across 11 sites in 5 countries.
Detailed Summary
Thet study aims to estimate the prevalence of ALK rearrangement in the Middle East North Africa population by using the Ventana ALK-IHC method for ALK protein detection in retrospective NSCLC clinical samples, \& to evaluate the association of ALK rearrangement with clinical and pathological parameters of NSCLC patients in MENA.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesEgypt, Lebanon, Morocco, Saudi Arabia, United Arab Emirates
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionFeb 2018
TodayJul 2026
First PostedDec 2, 2014
Enrollment StartJan 21, 2015
Primary CompletionFeb 11, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.6 years ago